NCT07207239

Brief Summary

The primary aim of the study is to find the combination of neuroimaging-related markers, demographics, and clinical characteristics that predict the response of patients with therapy-resistant depression to theta-burst rTMS treatment. The secondary aim is to monitor the cognitive effects of TMS therapy.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for not_applicable

Timeline
26mo left

Started Jun 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress30%
Jun 2025Jun 2028

Study Start

First participant enrolled

June 13, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 10, 2025

Completed
23 days until next milestone

First Posted

Study publicly available on registry

October 3, 2025

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 13, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 13, 2028

Last Updated

October 3, 2025

Status Verified

September 1, 2025

Enrollment Period

3 years

First QC Date

September 10, 2025

Last Update Submit

September 28, 2025

Conditions

Keywords

TMStherapy resistant depressionEEGMRIneuroimaging

Outcome Measures

Primary Outcomes (1)

  • Clinical symptoms

    The primary outcome measures are the clinical symptoms of depression measured by a clinician with the Montgomery-Åsberg Depression Rating Scale.

    120 days

Secondary Outcomes (6)

  • Neuroimaging characteristics

    120 days

  • Patient profile

    120 days

  • Cognitive functioning/Spatial working Memory

    120 days

  • Cognitive functioning/Executive function

    120 days

  • Cognitive functioning/reaction time

    120 days

  • +1 more secondary outcomes

Study Arms (1)

TB-rTMS

EXPERIMENTAL
Device: repetative Transcranial Magnetic Stimulation (rTMS), theta-burst protocol

Interventions

Theta-burst rTMS treatment stimulates the left Dorsolateral Prefrontal Cortex (DLPFC). The TBS parameters the investigators adopted follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 100% active motor threshold. The investigators plan to deliver 1800 stimuli to the left DLPFC daily in 9.5-minute blocks for four weeks.

TB-rTMS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diagnosis of depression
  • years of age
  • Beck depression inventory score above 12 (screening)
  • MADRS score above 6 (baseline)

You may not qualify if:

  • serious cognitive impairment
  • mental retardation
  • history of head injury with loss of consciousness for more than 1 hour
  • alcohol or drug abuse within the past 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Psychiatry and Psychotherapy

Budapest, Pest County, 1083, Hungary

Location

MeSH Terms

Conditions

Depressive Disorder, Treatment-Resistant

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

September 10, 2025

First Posted

October 3, 2025

Study Start

June 13, 2025

Primary Completion (Estimated)

June 13, 2028

Study Completion (Estimated)

June 13, 2028

Last Updated

October 3, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations